{{Rsnum
|rsid=13010627
|Gene=CASP10
|Chromosome=2
|position=201209375
|Orientation=plus
|ReferenceAllele=G
|MissenseAllele=A
|GMAF=0.02847
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=CASP10
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 8.0 | 92.0
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 0.0 | 0.0 | 100.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 1.7 | 8.6 | 89.7
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 11.8 | 88.2
| HapMapRevision=28
}}Previous studies had suggested that the minor allele of this SNP might influence breast cancer. However, a 2009 European study of 30,000 breast cancer cases, compared to 30,000 controls, found no association, or as they put it, "persuasive evidence against an overall association between invasive breast cancer risk and (this SNP)".{{PMID|19423537|OA=1
}}

{{omim
|id=603909
|rsnum=13010627
}}

{{ClinVar
|rsid=13010627
|Reversed=0
|FwdREF=G
|FwdALT=A
|REF=G
|ALT=A
|RSPOS=202074098
|CHROM=2
|GMAF=0.0284
|dbSNPBuildID=121
|SSR=0
|SAO=1
|VP=0x05036800000015051f110100
|GENEINFO=CASP10:843
|GENE_NAME=CASP10
|GENE_ID=843
|WGT=0
|VC=SNV
|CLNALLE=1
|CLNHGVS=NC_000002.11:g.202074098G>A
|CLNSRC=GeneReviews
|CLNORIGIN=0
|CLNSRCID=NBK1108
|CLNSIG=5
|CLNCUI=C1858968
|CLNDBN=Autoimmune lymphoproliferative syndrome, type 2
|Disease=Autoimmune lymphoproliferative syndrome
|CLNACC=RCV000020930.1
|Tags=PM;PMC;S3D;SLO;VLD;G5;HD;GNO;KGPhase1;KGPilot123;KGPROD;OTHERKG;PH3;LSD;OM
|CAF=0.9715; 0.02847
|CLNDSDB=GeneReviews:MedGen:OMIM:Orphanet
|CLNDSDBID=NBK1108:C1858968:603909:3261
|COMMON=1
}}

{{PMID Auto
|PMID=10412980
|Title=Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II.
}}

{{GET Evidence
|gene=CASP10
|aa_change=Val410Ile
|aa_change_short=V410I
|impact=protective
|qualified_impact=Low clinical importance, Likely protective
|inheritance=dominant
|quality_scores=Array
|dbsnp_id=rs13010627
|overall_frequency_n=510
|overall_frequency_d=10758
|overall_frequency=0.0474066
|n_genomes=1
|n_genomes_annotated=0
|n_haplomes=1
|n_articles=2
|n_articles_annotated=2
|qualityscore_in_silico=1
|qualitycomment_in_silico=Y
|qualityscore_case_control=4
|qualitycomment_case_control=Y
|qualityscore_familial=0
|qualityscore_severity=3
|qualitycomment_severity=Y
|qualityscore_treatability=3
|qualitycomment_treatability=Y
|gene_in_genetests=Y
|pph2_score=0.874
|genetests_testable=Y
|genetests_reviewed=Y
|nblosum100=-4
|autoscore=5
|n_web_uneval=9
|variant_evidence=0
|clinical_importance=1
|summary_short=Reported to have a protective effect on breast cancer. If the lifetime risk of breast cancer is 12%, women with this variant may have a lower risk of 8-9% (30% less than average).
}}

{{PMID Auto
|PMID=23212337
|Title=Role of CASP-10 gene polymorphisms in cancer susceptibility: a HuGE review and  meta-analysis
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}